

Canine mammary cancer: clinical implications with specific focus on the HER-2 gene

Alejandro Clavijo-Maldonado*, Enio Ferreira, Carlos Vargas-Hernández and Fredy A. Rivera-Páez



Abstract

Canine mammary cancer (CMC) is one of the most common neoplasms in intact females in comparison to other species. Several risk factors have been identified, including breed, genetic predisposition, age, reproductive history, hormonal influence, diet, and body condition, in addition to previous lesions to the mammary gland, such as mammary atypical hyperplasia. An understanding of the genetic markers for the disease and a clinical approach are important for establishing a specific therapy that can allow adequate patient survivorship. Overexpression of the HER-2 gene in canines and humans is associated with a poor clinical prognosis,

mainly short survivorship, although the clinical relationship is not clear. The incidence of HER-2 in female dogs can range from 29.7% to 38%. However, overexpression of HER-2 is not necessarily associated with malignancy processes of the mammary tissue, although it participates in cellular proliferation. Finally, canines remain one of the most important models for comparative oncology with humans due to the great similarity in the spontaneous presentation and development of cancer, and in the high homology in the amino acid sequence.

Key words: *c-erbB2; diagnostic; malignant mammary tumour; prognosis; risk factors*

Overview

The use of animal models for research on genetic human pathologies poses multiple advantages, including the

greater size of laboratory specimens that facilitates their management (Lindblad-Toh et al., 2005; Uva et al.,

Alejandro CLAVIJO-MALDONADO*, Esp., (Corresponding author address: e-mail: alejandrocvmvz@misena.edu.co), Grupo de Investigación GEBIOME, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas y Naturales, Universidad de Caldas, Manizales, Colombia, Grupo de Propiedades Ópticas de Materiales, Departamento de Física y Química, Universidad Nacional de Colombia Sede Manizales, Manizales, Colombia; Enio FERREIRA, PhD, Instituto de Ciências Biológicas, Departamento de Patologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brasil; Carlos VARGAS-HERNÁNDEZ, PhD, Grupo de Propiedades Ópticas de Materiales, Departamento de Física y Química, Universidad Nacional de Colombia Sede Manizales, Manizales, Colombia; Fredy A. RIVERA-PÁEZ, PhD, Grupo de Investigación GEBIOME, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas y Naturales, Universidad de Caldas, Manizales, Colombia

2009), highly similar tissue development and architecture, and the involvement of similar genes. The latter enables us to identify and understand the clinical, pathological, and genetic mechanisms involved in the onset and development of cancer (expression). Studies using canines represent an ideal solution to reduce the gap between animal models with naturally developed diseases and facilitate extrapolations to human medicine (Rowell et al., 2011).

Mammary cancer (MC) is a highly complex disease due to its heterogeneous histopathology, biological behaviour, and responses to systemic interventions (Geleick et al., 1990; Viale, 2012). Furthermore, it is considered a worldwide public health issue (Uribe et al., 2013). Canine mammary cancer (CMC) is one of the most important pathologies in veterinary medicine, particularly in non-spayed female dogs (Schneider et al., 1969; Sleenckx et al., 2011; Beck et al., 2013). Given the multifactorial origin of the disease, prevention and treatment is complex (Perez-Alenza et al., 2000). CMC is among the main causes of mortality in females and this tumour pathology has the greatest incidence compared to other domestic species (Cruz, 1999). CMC corresponds to almost 50% of all canine tumours (Misdorp et al., 1999; Dhimi et al., 2010), with an incidence estimated to be three times higher than in women (Kumaraguruparan et al., 2006; Dhimi et al., 2010). In addition, 50% to 70% of canine mammary tumours (CMT) are considered malignant (Moe, 2001; Merlo et al., 2008; Salas et al., 2015).

Canines as a model for naturally occurring human breast cancer (BC)

Canines are the most common pet worldwide, and it is estimated that 33%

people over 15 years old own a dog. This is the most common pet in Latin America, Asia and Oceania, and second most common in Europe (GfK, 2016). This is due in part to ongoing social changes in recent years, which have led to the role of pets as “family members” (Sharpe, 2017), even influencing the owners’ finances (Pet Census, 2016). As a consequence, companion animals, particularly canines, are an excellent model for studying complex human diseases (Rowell et al., 2011).

At the genome level, canines share ~650 Megabases (Mb) of ancestral sequence with humans (Lindblad-Toh et al., 2005; Pang and Argyle 2009). Also, many uni- or multifactorial physiological disorders constitute unique models for human diseases (Yang et al., 1999; Starkey et al., 2005). Nearly 400 hereditary diseases in canines have an equivalent in humans, many of which have been described and named in the same manner (Starkey et al., 2005). Therefore, as with murine models, there is increasing interest in undertaking comparative oncology research with canines (MacEwen, 1990; Pinho et al., 2012). In canines, the evolution period of cancer is significantly less than in humans, as is the response to treatment, enabling preclinical studies in cancer development (Uva et al., 2009; Peruzzi et al., 2010). As such, the time period for evaluating cancer treatment success in canines is 18 months, while at least seven years are required in humans (Paoloni and Khanna, 2008).

Canines can develop MC spontaneously (Macewen et al., 1982; Jaillardon et al., 2015) or it can be hereditary, though there is insufficient evidence despite the evident homologies with humans (Szabo et al., 1996; Goebel and Merner, 2017). The underlying genetic complexity of tumour development (Aguirre-Hernández et al., 2009), biological behaviour, growth patterns, morphology, tumour progression, metastasis patterns, histological

types, and therapeutic response are highly similar in humans (Starkey et al., 2005; Paoloni and Khanna, 2008; Pang and Argyle, 2009; Tamburini et al., 2009; Peruzzi et al., 2010; Tang et al., 2010; Gupta et al., 2012). The epidemiological characteristics are also similar between the two species (Cassali, 2013; Vascellari et al., 2016), although for some cancer types, disease progression is more aggressive in canines than in humans (Meirelles, 2010; García, 2013). Therefore, the establishment of oncology research protocols for the early detection of cancer in canines will enable its future extrapolations, followed by advantages for medicine and for human and animal survivorship.

CMC risk factors and pathogenesis

Different factors influence CMC development, including breed and genetic predisposition, age, reproductive history, hormonal activity, diet, and obesity (Sleeckx et al., 2011). Previous lesions, such as mammary atypical hyperplasia, can also increase the risk of CMC presentation (Dupont et al., 1993; Page et al., 2003; Ferreira et al., 2014).

Breed and genetic predisposition: Purebreds show a higher predisposition (Hemanth et al., 2015; Sahabi et al., 2015). French Poodle, English Springer Spaniel, English Spaniels, Cocker Spaniels, German Shepherds, Maltese, Yorkshire Terrier, and Dachshunds display a high incidence of CMC (Borge et al., 2011; Sleeckx et al., 2011; Caicedo et al., 2012; Burrai et al., 2015; Campos et al., 2015). Dhami et al. (2010) and Hemanth et al. (2015) reported other breeds that are highly susceptible to CMC development, including the Doberman, Labrador Retriever, Great Dane, Pomeranian, and Spitz (Dhami et al., 2010; Hemanth et al., 2015). Meanwhile, other breeds have been identified as low risk: Border Collie, Shetland Sheepdog, Bernese Mountain,

and Saint Bernard (Borge et al., 2011). However, these results could be biased by the ownership popularity of certain breeds compared to others (Vidales and Eslava 2007; Dhami et al., 2010). Yet, there is a consensus regarding a higher cancer predisposition of small breeds compared to large breeds (Chang et al., 2005; Hsu et al., 2009; Sahabi et al., 2015).

Age: In addition to genetic predisposition, age also plays a fundamental role. CMC presentation is more frequent in mid to older age females, and an average age of six years has been defined as the “cancer age” (Perez-Alenza et al., 2000; Dhami et al., 2010; Shinoda et al., 2014). In addition, a high incidence is also observed between 9 and 10 years (Støvring et al., 1997; Hsu et al., 2009; Caicedo et al., 2012; Campos et al., 2015., Sahabi et al., 2015). However, there are also reports of age averages under 8.4 years (Chang et al., 2005), while authors such as Hemanth et al. (2015) found a higher age range of 6 to 10 years, with a reduction in frequency after 12 years.

Reproductive history: Non-spayed females are more susceptible to CMC than spayed females (Chang et al., 2005; Sleeckx et al., 2011; Hemanth et al., 2015; Sahabi et al., 2015). Females spayed before their first oestrous cycle have approximately a 0.5% risk of developing CMC, while ovariectomy after the second cycle increases the risk to 8%, and to 26% after three cycles (Schneider et al., 1969). Therefore, ovarian hormone ablation through ovariectomy performed during early life dramatically decreases dose-dependent steroid exposure, thus reducing the risk of early mammary tumour development (Sorenmo et al., 2011). Additionally, ovariectomy increases the survival index when established as a therapeutic measure for CMC (Hsu et al., 2009), since the survival index of females with CMC that undergo ovariectomy has been found to

nearly double compared to non-spayed females (Chang et al., 2005). Nevertheless, there are differences among cancer types regarding the therapeutic impact of ovariectomy, e.g. in females with complex carcinoma compared to simple (Chang et al., 2005).

Hormone influence: Ovarian steroid hormones and products with medroxyprogesterone acetate (MPA) produce a proliferative effect on the mammary tissue, thus stimulating growth and increasing the risk of mammary tumour development (Sleeckx et al., 2011). Steroid hormones (mainly oestrogens and progesterone) participate in the normal development of the mammary tissue and play a key role in the early stages of CMC pathogenesis (Sorenmo et al., 2011). Therefore, an ovariectomy after the second oestrous cycle does not guarantee full protection from possible tumour development (Schneider et al., 1969). This can be explained by the fact that both oestrogen receptors (ER) and progesterone receptors (PR) are present in high amounts in normal tissues and benign lesions, leading to accumulation and availability in the mammary tissue (Macewen et al., 1982; Rutteman et al., 1988; Clamp et al., 2003; Rao, 2008), as compared to cancerous or metastatic tissues. Nevertheless, there is a notable presence of 17β -[^3H] oestradiol (Macewen et al., 1982). Furthermore, MPA, a progestin used to prevent oestrous or treat false pregnancy, is known to increase the risk of CMC development (Rutteman et al., 1988; Støvring et al., 1988). MPA induces overproduction of the growth hormone (GH), which induces the development of dysplasia and benign tumours (Perez-Alenza et al., 2000). The interaction of the GH in the mammary tissue stimulates the insulin-like growth factor 1 (IGF-1).

Prolactin (PRL) is a 199 amino acid peptide with a molecular weight of 23 kDa (Freeman et al., 2000), synthesized

by the anterior pituitary gland. This peptide displays a luteotrophic action that is especially important during the second half of pregnancy (Verstegen-Onclin and Verstegen, 2008; Rufo et al., 2016), participates in cellular development and differentiation of the canine mammary gland (Jöchle, 1997; Rufo et al., 2016), and carries out lactogenic activity (Michel et al., 2012a), among other functions. Although the role of PRL in tumour development in the canine mammary gland is still under debate, several studies have proposed that tumour genesis in the pituitary gland is associated with decreased secretory activity (El Etreby et al., 1980). This agrees with later studies that reported a reduced expression of the prolactin receptor (PRLR) (Michel et al., 2012b). In addition, findings have shown high levels of PRL in CMC compared to benign lesions or hyperplasias (Queiroga et al., 2005). These authors indicate that most PRL present in cancerous tissues is not of pituitary origin. This has been demonstrated in humans (Ginsburg and Vonderhaar, 1995), where there might be an autocrine and paracrine effect (Ben-Jonathan et al., 2002; Clevenger et al., 2003).

Diet: Homemade food, such as those rich in fat and beef and pork, increase susceptibility to CMC compared to diets rich in poultry or balanced diets (Alenza et al., 2000; Sleeckx et al., 2011).

Overweight and obesity: Body fat ranges from 15 to 25% in healthy animals, while more than 30% is considered obesity (Burkholder et al., 2000). However, this relationship tends to be narrower as age increases (German, 2006). Body mass and overweight status can be assessed through morphological analysis with determination of body fat (Burkholder et al., 2000), e.g. the Canine Body Mass Index (IMCC) (Muller et al., 2008) or Escore of Body Condition (ECC) (Laflamme, 1997). Adipocytes are

the functional unit of fatty tissue (Khan et al., 2015). They have high metabolic activity and are highly sensitive to nervous, nutritional and hormonal control (Stephens, 2012) and about 95% of the cell weight is represented by triglycerides (Khan et al., 2015). However, being overweight alters the release of certain substances, including leptin (German et al., 2010). This protein hormone specific to adipocytes of 167 amino acids, has been known for its appetite control effects (Facey et al., 2017) and is linked to the regulation of body mass (Hassink et al., 1996).

In dogs and humans, an increase in leptin has been found when adipose tissue is more abundant (Maffei et al., 1995; Gayet et al., 2004; Kil and Swanson, 2010), implying cell proliferation by stimulation of the IGF-1 or somatomedin and promotion of angiogenesis (Renehan et al., 2006). In BC, the leptin receptor (ObR) and Human Epidermal Growth Factor Receptor type 2 (HER-2) can be co-expressed, which reduces the effectiveness of HER-2 treatments (Fiorio et al., 2008), since ObR can mediate HER transactivation-2 (Soma et al., 2008), although this is controversial (Santillán et al., 2012). The positive relationship between ObR and HER-2 has also been observed in animals (rodent models) with mammary tumour (García-Robles et al., 2013), although this interaction is not yet clear (Lim et al., 2015).

In female dogs, obesity during the first year of life markedly increases the risk of cancer, since several carcinogenic events occur in the mammary gland during this period, although there is no clarity on this mechanism (Sonnenschein et al., 1991; Perez-Alenza et al., 2000; Sorenmo et al., 2011; Lim et al., 2015). Several findings have shown that the risk is similar if a female is obese at least one year prior to being diagnosed with CMC (Shofer et al., 1989).

Clinical aspects and diagnosis of CMC

Clinically, tumour masses are the main warning of abnormality in the mammary glands of female dogs. The size of these masses can range from 0.5 cm to 21 cm in diameter (Chang et al., 2005; Hsu et al., 2009). Consequently, the clinical significance of canine tumour masses indicates that small and hard masses are more likely benign, while larger masses generally display ulceration and are histologically malignant (Hemanth et al., 2015). Thus, the latter result in a more unfavourable prognosis (Hsu et al., 2009).

All mammary glands can be involved in the development of CMC, whether initially one gland is involved or a combination of them, and these can show the same or different histological features (Perez-Alenza et al., 2000; Goebel and Merner, 2017). There is no tendency towards one side more than the other (Chang et al., 2005; Hsu et al., 2009; Hemanth et al., 2015), though findings have shown that the caudal mammary glands (glands 3, 4 and 5) are more affected than the thoracic pairs (1 and 2) (Chang et al., 2005; Hsu et al., 2009). In consequence, the inguinal zone is most affected, while the least affected is the caudal thoracic sector (Hemanth et al., 2015).

Additionally, lymphatic drainage in healthy females is ipsilateral (towards the same side) and there is no evidence of drainage towards the contralateral lymph nodes (LN) (Pereira et al., 2003; Pereira et al., 2008), which is one of the differentiating factors in neoplastic glands (Patsikas et al., 2006). However, not all CMC types behave in the same manner, e.g. epithelial type neoplasms, such as carcinomas, generate metastasis through the lymphatic system, while mesenchymal neoplasms, such as sarcomas, achieve metastasis through capillaries and veins (Sorenmo et al.,

2011). There are correlations between CMC patient survival and the number of affected LN, where average survivorship decreases with increasing number of affected LN (Carter et al., 1989; De Araújo et al., 2015). Tumour size and LN condition are independent prognostic factors; however, they are additive (Carter et al., 1989), since a larger tumour diameter is related to metastasis to the lymph node (Chang et al., 2005). This fact indicates a direct relation between these two factors.

CMC and genetic markers

In hereditary human BC, alterations of the suppressor gene p53 and mutations in suppressor genes BRCA1 and BRCA2 (Breast Cancer 1, 2) are mainly involved (Overgaard et al., 2000; Honrado et al., 2006; Olivier et al., 2006; Pérez-Losada et al., 2011). In sporadic MC, there is an involvement of modulators of cellular proliferation, including alterations in ER, which are classified into three groups: classic ER α , ER β , and the most recently described, GPR30 (G protein-coupled receptor 30) (Prossnitz et al., 2007; Hazell et al., 2009; Prossnitz and Maggiolini, 2009). The first two ER groups belong to the superfamily of nuclear receptors that regulate elements at the nuclear level through MAPK-type responses (*Mitogen-Activated Protein Kinases*), PI3K (*Phosphoinositide (PI) 3-Kinase*), and cAMP (*cyclic adenosine monophosphate*). Alterations in these two receptors lead to cellular proliferation, growth, and survival. ER are implied in high resistance to treatments and development of metastasis, in co-expression with the HER-2 gene (Filardo et al., 2006). Another group consists of *Transforming growth factor* (TGF β), which includes three members (TGF β I-III). A reduction in the expression of TGF β enables the development of MC and eventual metastasis (Landis et

al., 2005; Dong et al., 2007). In addition, PGDF (Platelet-Derived Growth Factor) receptors include two types, PGDFR α and β , which are related to cellular proliferation and differentiation. Tumour invasion capacity has been correlated with co-expression of PGDFR α and HER-2 (Carvalho et al., 2005). Finally, the Protease-activated receptor (PAR) participates in the modulation of cancer growth (Ceballos and Hernández, 2008). PAR1 mediates calcium signalling, transcription processes, and mitogenesis (Coughlin, 2000). HER-2 contributes to PAR1 activation, therefore, providing high prognostic value (Ceballos and Hernández, 2008).

In canines, mutations in genes with high or low penetrance in cancer considerably increase the risk of CMC presentation. Single Nucleotide Polymorphisms (SNP) in coding regions can lead to alterations in protein structure or function (Borge et al., 2011). Genes that show different risk levels have been the most studied, including breast cancer susceptibility genes 1 and 2 (BRCA1, BRCA2), tumour protein p53 (TP53), phosphatase and tensin homolog (PTEN), checkpoint kinase 2 (CHEK2), ataxia telangiectasia mutated (ATM), and human epidermal growth factor receptor-2 (HER-2) (Hsu et al., 2009; Borge et al., 2011).

CMC and clinical implications of the HER-2 gene

In women with BC, the overexpression of HER-2 (HER-2 positive state) is found between 20% and 30%, and is generally correlated with a high phenotypic aggressiveness and resistance to cytotoxic and endocrine therapies (González et al., 2007; Fehm et al., 2007; Savino et al., 2009; Park et al., 2014). The latter leads to a poor clinical prognosis, mainly short survivorship (Slamon et al., 1987; Gambini et al., 2003; Ross et al., 2003),

and in both humans and canines, the prognosis is reserved for up to two years after surgery (Ressel et al., 2013).

The oncogene HER-2/*neu* was initially isolated from neuroectodermal tumours in rats and compared to its homologues in humans and rabbits; therefore, *neu* corresponds to neuroblastoma (Shih et al., 1981). In humans, HER-2/*neu* maps to chromosome 17q 12-21.32 (Akiyama et al., 1986; Fukushima et al., 1986; Popescu et al., 1989; Fehm et al., 2007; Finn et al., 2009; Krishnamurti and Silverman, 2014). In canines, the gene is located on chromosomes 9 and 5 (Yang et al., 1999); however, it has also mapped to chromosome 1q13.1 through fluorescence *in situ* hybridization (FISH) (Murua Escobar et al., 2001). HER-2/*neu* is a membrane protein of 185-kDa (Manguire et al., 1989), conformed by three domains: a transmembrane lipophilic domain, an extracellular domain (ECD) (105 -kDa), and an intracellular tyrosine kinase domain (Ha et al., 2015; Di Gioia et al., 2015). HER-2 carries out an important role in regulating cellular growth and differentiation (Yarden, 2001). However, it has gained importance given its participation in the physiopathological progression of the mammary tumour and low response to treatments (Akiyama et al., 1986; Lüftner et al., 2003).

In humans, the clinical significance of HER-2 is relevant, because it is overexpressed in early stages of cancer development. In consequence, it has become a therapeutic target (Hanna, 2001; Yarden, 2001; Wilson et al., 2002; Reddy et al., 2004; Finn et al., 2009; Krawczyk et al., 2009; Onitilo et al., 2009; Page et al., 2011; Soares et al., 2016). Yet, unlike the other receptors (HER-1, HER-3, and HER-4), HER-2 oncogenesis is attributed to an increase in the expression of a non-mutated receptor. As a result, there is an increase in tyrosine-kinase activity, which induces cellular transformation (Siegel et

al., 1994; Biscardiet et al., 2000; Yarden 2001; Stefano et al., 2004; Moasser, 2007). Therefore, HER-2 is closely related with the rate of cancer progression (González et al., 2007). This is due to a deletion in exon 16 of the extracellular domain (Siegel et al., 1994) and a polymorphism in codon 655 (Papewalis et al., 1991). Hence, MC with overexpression of HER-2 highly correlates with metastasis in regional lymph nodes and, for this reason, HER-2 is used as a prognosis marker in relation to other proteins p53, Ki67, ER, and PR (Selvarajan et al., 2004).

There is a 29.7% incidence of HER-2 overexpression in female canines diagnosed with malignant mammary tumour (Hsu et al., 2009). Later studies showed incidence rates of 28.6% (Ressel et al., 2013), 38% (Shinoda et al., 2014), 37.5% (Burrai et al., 2015) and 32.1% (Campos et al., 2015). However, the results regarding HER-2 expression levels are not yet clear (Hsu et al., 2009; Ressel et al., 2013). HER-2 overexpression is seemingly not strictly associated with the initial stages of atypical cellular proliferation (Ferreira et al., 2014), indicating a high complexity in terms of establishing the most adequate prognosis and therapy for each type of CMC (Ressel et al., 2013).

In canines, it is likely that HER-2 only participates in proliferation and not in the malignancy process of the mammary tissue during tumour formation (Hsu et al., 2009; Ressel et al., 2013). Nevertheless, this can vary, since there have been reports of CMC processes with amplification or overexpression of HER-2 (Rungisipat et al., 1999), and of others with no association to HER-2 (De las Mulas et al., 2003). This poses a challenge for prognosis (Dutra et al., 2004), as findings are not clear regarding the effects of HER-2 on the survivorship rate in comparison to other genes (Hsu et al., 2009; Shinoda et al., 2014). However, a HER-2 positive state means an unfavourable prognosis, both for women (Savino et al., 2009) and

in most canine female cases (Hsu et al., 2009; Ressel et al., 2013).

HER-2 as a tumour marker in CMC

A tumour marker (TM) is a molecule (glycoprotein, generally) that can be produced by normal cells and tumour cells, although levels are higher in the presence of cancer (Hermida et al., 2016). In cancer, concentrations of TM can be produced by both normal cells and cancer cells, and these substances are detectable in biological fluids (Romero et al., 2002; Almeida et al., 2007). TMs may be tumour-specific proteins (tumour antigen specific), nonspecific protein tumour markers associated with malignant cells, or specific proteins overexpressed in malignant cells (Lindblom and Liljegren, 2000; Romero et al., 2002). No TM is totally sensitive and specific, but together with other clinical procedures can take specific therapeutic decisions (Koshida et al., 1996; Lindblom and Liljegren, 2000; Hermida et al., 2016).

HER-2/*neu* (HER-2) is a proto-oncogene that encodes a glycoprotein that stimulates cell proliferation and differentiation in normal epithelial cells (Yarden and Sliwkowski, 2001; Farzadnia et al., 2010). In humans, overexpression of the HER-2 protein has been found in 20 to 30% of invasive breast cancer cases (Slamon et al., 1987; Wolff et al., 2013). The concentration in serum has an important prognostic value (Andrulis et al., 1998; Sjögren et al., 1998; Agrup et al., 2000) and it has high influence on treatment decisions (Leyland-Jones, 2002).

In human breast cancer (HBC), HER-2 levels in blood serum have been studied in metastatic cancer (Jensen et al., 2003). Serum concentrations of 18.5% have been reported (Carney et al., 2003), and 13.4% with significant correlation with tumour size and clinical grade by

immunohistochemical analysis (IHC) (Harris et al., 2001) and ELISA in primary HBC (Pallud et al., 2005). Other studies have not found a positive correlation between clinical-pathological variables and elevated serum levels (Kong et al., 2006). The cut-off value for serum measurements of HER-2 should be determined for each type of population (Ellis et al., 2000; Rakha et al., 2015) due to the little relation that there could be with the amplification of the gene or the overexpression of the protein (Kong et al., 2006).

The BLAST alignment of HER-2 reveals a 92% homology in the amino acid sequence between humans and canines (Singer et al., 2012). However, the use of human test kits for enzyme-linked immunosorbent (ELISA) to measure concentrations of HER-2 in dogs did not significantly differentiate between healthy patients and those with cancer (Campos et al., 2015). However, the correlation of serum levels of HER-2 with tumour size, high histological grade, mitotic index and nuclear polymorphism indicated a poor prognosis (Dutra et al., 2004; Hsu et al., 2009; Muhammadnejad et al., 2012; Kaszak et al., 2018), although this relationship is controversial (Kim et al., 2011; Ressel et al., 2013). Additionally, reduced expression has been reported in the presence of aggressive tumours such as ductal carcinoma *in situ* (DCIS) (Silva et al., 2014), unlike that found in feline mammary cancer (FMC) (Soares et al., 2016).

Currently, it has been difficult to determine the similarities or differences in the overexpression of HER-2 between humans and canines. In canines, we find the deletion of exon 16 or the absence of polymorphism of codon 655, yet there is a polymorphism in exon 14 (Hsu et al., 2009). Nonetheless, it is important to differentiate between diagnostic methods with high sensitivity, in order to clearly establish similarities and relations in

this gene between humans and canines (Savino et al., 2009).

Conclusions

The differences between the overexpression of HER-2 in human BC and CMT are not yet clear. Despite recognizing the importance of HER-2, the clinical usefulness of its detection in animal medicine is still unclear, since the relationship between overexpression of HER-2 and CMC may be due to the interaction of several genes and not to the activity of the gene itself. In addition, care must be taken to determine HER-2, since it is overexpressed in other types of tumours, therefore it is necessary to supplement the clinical correlation with other clinical analyses. In humans, high levels of ECD in primary BC have a high diagnostic, prognostic and therapeutic value, while in canines, the pattern of presentation is not clear and survival findings are controversial. Given the high complexity involved in monitoring HER-2 in female dogs, it is important to develop studies with simple, minimally invasive methods that would allow for early detection.

Acknowledgments

To the Vicerrectoría de Investigaciones y Posgrados, Universidad de Caldas, for providing funding for the research projects titled "Expression of ER-A, MUC1, and HER-2 genes, and their relevance in the early diagnosis of canine mammary tumors in Manizales, Caldas" Code. 0298218, and "Biocompatible sensors based on gold and silver nanostructures for breast cancer diagnosis" Code. 0923517 of the grant "Convocatoria Conjunta para el Fomento de la Investigación Aplicada y Desarrollo Tecnológico" between the Universidad de Caldas and Universidad Nacional de Colombia - Sede Manizales. To the Ethics Committee for Animal Experimentation-CEEAA-Cód. 15061601.

References

1. AGRUP, M., O. STÅL, K. OLSEN and S. WINGREN (2000): C-erbB-2 overexpression and survival in early onset breast cancer. *Breast. Cancer. Res. Treat.* 63, 23-29.

2. AGUIRRE-HERNÁNDEZ, J., B. S. MILNE, C. QUEEN, P. C. M. O'BRIEN, T. HOATHER, S. HAUGLAND and D. R. SARGAN (2009): Disruption of chromosome 11 in canine fibrosarcomas highlights an unusual variability of CDKN2B in dogs. *BMC. Vet. Res.* 5, 27.
3. AKIYAMA, T., C. SUDO, H. OGAWARA, K. TOYOSHIMA and T. YAMAMOTO (1986): The Product of the Human c-erbB-2 Gene: A 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity. *Science* 232, 1644-1646.
4. ALMEIDA, J. R. C., N. L. PEDROSA, J. B. LEITE, T. R. F. PRADO, V. C. HENRIQUES and A. A. C. ALEXANDRE (2007): Marcadores Tumorais: Revisão de Literatura. *Rev. Bras. Cancerol.* 53, 305-316.
5. ANDRULIS, I. L., S. B. BULL, M. E. BLACKSTEIN et al. (1998): neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. *Toronto Breast Cancer Study Group. J. Clin. Oncol.* 16, 1340-1349.
6. BECK, J., S. HENNECKE, K. BORNEMANN-KOLATZKI, H. B. URNOVITZ, S. NEUMANN, P. STRÖBEL and E. SCHÜTZ (2013): Genome Aberrations in Canine Mammary Carcinomas and Their Detection in Cell-Free Plasma DNA. *PLoS. One* 8, 1-16.
7. BEN-JONATHAN, N., K. LIBY, M. MCFARLAND and M. ZINGER (2002): Prolactin as an autocrine/paracrine growth factor in human cancer. *Trends. Endocrinol. Metab.* 13, 245-250.
8. BISCARDI, J. S., R. C. ISHIZAWAR, C. M. SILVA and S. J. PARSONS (2000): Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. *Breast Cancer Res.* 2, 203-210.
9. BORGE, K. S., A. L. BØRRESEN-DALE and F. LINGAAS (2011): Identification of genetic variation in 11 candidate genes of canine mammary tumour. *Vet. Comp. Oncol.* 9, 241-250.
10. BURKHOLDER, W. J. and P. W. TOLL (2000): Obesidad. In: Hand, M. S.: *Nutrición clínica en pequeños animales*, 4th Ed. Inter-Médica (475-508).
11. BURRAI, G. P., A. TANCA, M. R. DE MIGLIO, M. ABBONDIO, S. PISANU, M. POLINAS and E. ANTUOFERMO (2015): Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer? *Tumor. Biol.* 36, 9083-9091.
12. CAICEDO, J. A., C. A. IREGUI, M. E. CABARCAS and B. J. ACOSTA (2012): Estudio comparativo de la frecuencia de tumores mamarios según sexo, edad y tipo histológico en caninos y humanos en los laboratorios de patología anatómica de la Universidad Nacional de Colombia sede Bogotá. *Revista Colombiana de Ciencia Animal* 5, 52-66.
13. CAMPOS, L. C., J. O. SILVA, F. S. SANTOS, M. R. ARAÚJO, G. E. LAVALLE, E. FERREIRA and G. D. CASSALI (2015): Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer. *J. Vet. Diagn. Invest.* 27, 531-535.
14. CARNEY, W. P., R. NEUMANN, A. LIPTON, K. LEITZEL, S. ALI and C. P. PRICE (2003): Potential clinical utility of serum HER-2/neu oncoprotein

- concentrations in patients with breast cancer. *Clin. Chem.* 49, 1579-1598.
15. CARTER, C. L., C. ALLEN and D. E. HENSON (1989): Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. *Cancer* 63, 181-187.
 16. CARVALHO, I., F. MILANEZI, A. MARTINS, R. M. REIS and F. SCHMITT (2005): Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. *Breast Cancer. Res.* 7, R788-R795.
 17. CASSALI, G. D. (2013): Comparative mammary oncology: canine model. *BMC Proc.* 7 (Suppl 2), K6.
 18. CEBALLOS, C. G. and R. N. A. HERNÁNDEZ (2008): Moduladores de Progresión en Cáncer de Mama. *Cancerología* 3, 41-49.
 19. CHANG, S., C. CHANG, T. CHANG and M. WONG (2005): Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). *J. Am. Vet. Med. Assoc.* 227, 1625-1629.
 20. CLAMP, A., S. DANSON and M. CLEMONS (2003): Hormonal and genetic risk factors for breast cancer. *Surgeon* 1, 23-31.
 21. CLEVENGER, C. V., P. A. FURTH, S. E. HANKINSON and L. A. SHULER (2003): The role of prolactin in mammary carcinoma. *Endocr. Rev.* 24, 1-27.
 22. COUGHLIN, S. R. (2000): Thrombin signaling and protease-activated receptors. *Nature* 407 (6801), 258-264.
 23. CRUZ, A. J. M. (1999): Ginecología. In: *Compendio de medicina and cirugía canina*, 1st Ed. Lealon, Medellín (183).
 24. DE ARAÚJO, M. R. L. C. CAMPOS, E. FERREIRA and G. D. CASSALI (2015): Quantitation of the Regional Lymph Node Metastatic Burden and Prognosis in Malignant Mammary Tumors of Dogs. *J. Vet. Intern. Med.* 29, 1360-1367.
 25. DE LAS MULAS, J. M., J. ORDÁS, Y. MILLÁN, V. FERNÁNDEZ-SORIA and S. RAMON Y CAJAL (2003): Oncogene HER-2 in canine mammary gland carcinomas. *Breast Cancer. Res. Treat.* 80, 363-367.
 26. DHAMI, M. A., P. H. TANK, A. S. KARLE, H. S. VEDPATHAK and A. S. BHATIA (2010): Epidemiology of canine mammary gland tumours in Gujarat. *Veterinary. World* 3, 282-285.
 27. DI GIOIA, D., M. DRESSE, M. D. MAYR, D. NAGEL, V. HEINEMANN and P. STIEBER (2015): Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. *Clin. Chim. Act.* 16-22.
 28. DONG, M., T. HOW, K. C. KIRKBRIDE, K. J. GORDON, J. D. LEE, N. HEMPEL and G. C. BLOBE (2007): The type III TGF- β receptor suppresses breast cancer progression. *J. Clin. Invest.* 117, 206-217.
 29. DUPONT, W. D., F. F. PARL, W. H. HARTMANN, L. A. BRINTON, A. C. WINFIELD, J. A. WORRELL, P. A. SCHUYLER and W. D. PLUMMER (1993): Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. *Cancer* 71, 1258-1265.
 30. DUTRA, A. P., N. V. M. GRANJA, F. C. SCHMITT and G. D. CASSALI (2004): c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors. *Braz. J. Med. Biol. Res.* 37, 1673-1681.
 31. EL ETREBY, M. F., R. MÜLLER-PEDDINGHAUS, R. A. S. BHARGAVA, M. R. FATH EL BAB, K. J. GRÄF and G. TRAUTWEIN (1980): The Role of the Pituitary Gland in Spontaneous Canine Mammary Tumorigenesis. *Vet. Pathol.* 17, 2-16.
 32. ELLIS, I. O., M. DOWSETT, J. BARTLETT, R. WALKER, T. COOKE, W. GULLICK, B. GUSTERSON, E. MALLON and P. B. LEE (2000): Recommendations for HER2 testing in the UK. *J. Clin. Pathol.* 53, 890-892.
 33. FACEY, A., L. DILWORTH and R. IRVING (2017): A Review of the Leptin Hormone and the Association with Obesity and Diabetes Mellitus. *J. Diabetes Metab.* 8, 1-3.
 34. FARZADNIA, M., N. T. MEIBODI, F. H. SHANDIZ, M. MAHMOUDI, M. M. BAHAR, B. MEMAR, S. AMOIAN, F. MAROOZI and N. MOHEGHI (2010): Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters. *Breast* 19, 489-492.
 35. FEHM, T., S. BECKER, S. DUERR-STOERZER, K. SOTLAR, V. MUELLER, D. WALLWIENER, N. LANE, E. SOLOMAYER and J. UHR (2007): Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. *Breast Cancer Res.* 9, R74.
 36. FERREIRA, E., A. C. BERTAGNOLLI, H. GOBBI and G. D. CASSALI (2014): HER-2 gene expression in atypical ductal hyperplasia associated with canine mammary carcinomas. *Arq. Bras. Med. Vet. Zootec.* 66, 609-612.
 37. FILARDO, E. J., C. T. GRAEBER, J. A. QUINN, M. B. RESNICK, D. GIRI, R. A. DELELLIS, M. M. STEINHOFF and E. SABO (2006): Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. *Clin. Cancer. Res.* 12, 6359-6366.
 38. FINN, R. S., R. GAGNON, A. DILEO, M. F. PRESS, M. ARBUSHITES and M. KOEHLER (2009): Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. *J. Clin. Oncol.* 27, 5552-5558.
 39. FIORIO, E., A. MERCANTI, M. TERRASI et al. (2008): Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. *BMC Cancer* 8, 305.
 40. FREEMAN, M. E., B. KANYICSKA, A. LERANT and G. NAGY (2000): Prolactin: structure, function, and regulation of secretion. *Physiol. Rev.* 80, 1523-1631.
 41. FUKUSHIGE, S., K. MATSUBARA, M. YOSHIDA, M. SASAKI, T. SUZUKI, K. SEMBA, K. TOYOSHIMA and T. YAMAMOTO (1986): Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. *Mol. Cell Biol.* 6, 955-958.

42. GAMBINI, C., A. R. SEMENTA, L. BONI, C. E. MARINO, M. CROCE, F. NEGRI, V. PISTOIA, S. FERRINI and M. V. CORRIAS (2003): Expression of HER2 / neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. *Cancer. Immunol. Immunother.* 52, 116-120.
43. GARCIA, A. B. (2013): Avaliação da expressão do receptor HER-2 em carcinomas mamários caninos. Dissertation. Faculdade de Medicina Veterinária, Universidade de Lisboa.
44. GARCÍA-ROBLES, M. J., J. E. SEGURA-ORTEGA and M. FAFUTIS-MORRIS (2013): The Biology of Leptin and Its Implications in Breast Cancer: A General View. *J. Interferon. Cytokine. Res.* 33, 717-727.
45. GAYET, C., E. BAILHACHE, H. DUMON, L. MARTIN, B. SILIART and P. NGUYEN (2004): Insulin resistance and changes in plasma concentration of TNF α , IGF1, and NEFA in dogs during weight gain and obesity. *J. Anim. Physiol. Anim. Nutr. (Berl.)* 88, 157-165.
46. GELEICK, D., H. MÜLLER, A. MATTER, J. TORHORST and U. REGENASS (1990): Cytogenetics of breast cancer. *Cancer. Genet. Cytogenet.* 46, 217-229.
47. GERMAN, A. J., V. H. RYAN, A. C. GERMAN, I. S. WOOD and P. TRAYHURN (2010): Obesity, its associated disorders and the role of inflammatory adipokines in companion animals. *The. Vet. J.* 185, 4-9.
48. GERMAN, A. J. (2006): Clinical risks associated with obesity in companion animals. *Waltham. Focus.* 16, 21-26.
49. GfK. (2016): Pet Ownership. Global GfK survey, 1-8.
50. GINSBURG, E. and B. K. VONDERHAAR (1995): Prolactin Synthesis and Secretion by Human Breast Cancer Cells. *Cancer. Res.* 55, 2591-2595.
51. GOEBEL, K. and N. D. MERNER (2017): A monograph proposing the use of canine mammary tumours as a model for the study of hereditary breast cancer susceptibility genes in humans. *Vet. Med. Sci.* 3, 51-62.
52. GONZÁLEZ, N. L. A., Á. A. GARAVITO, J. C. ECHEVERRI, V. S. JARAMILLO, C. R. D. SALAZAR and B. B. H. ARISTIZÁBAL (2007): Cáncer de mama: HER2 / neu, métodos diagnósticos y consideraciones clínicas. *Rev. Colomb. Cancerol.* 11, 40-57.
53. GUPTA, K., N. S. KUMAR, S. U. KUMAR, J. MOHINDROO, S. MAHAJAN, M. RAGHUNATH and K. SINGH (2012): Epidemiological Studies on Canine Mammary Tumour and its Relevance for Breast Cancer Studies. *IOSR. J. Pharm.* 2, 322-333.
54. HA, J. H., M. K. SEONG, E. K. KIM et al. (2014): Serial Serum HER2 Measurements for the Detection of Breast Cancer Recurrence in HER2-Positive Patients. *J. Breast Cancer* 17, 33-39.
55. HANNA, W. (2001): Testing for HER2 status. *Oncology.* 61 Suppl 2, 22-30.
56. HARRIS, L. N., V. LIOTCHEVA, G. BROADWATER et al. (2001): Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. *J. Clin. Oncol.* 19, 1698-1706.
57. HASSINK, S. G., D. V. SHESLOW, E. LANCEY, I. OPENTANOVA, V. CONSIDINE R. and J. F. CARO (1996): Serum Leptin in Children With Obesity: Relationship to Gender and Development. *Pediatrics* 98 (2 Pt 1), 201-203.
58. HAZELL, G. G. J., S. T. YAO, J. A. ROPER, E. R. PROSSNITZ, A. M. O'CARROLL and S. J. LOLAIT (2009): Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. *J. Endocrinol.* 202, 223-236.
59. HEMANTH, I., R. KUMAR, K. C. VARSHNEY, M. G. NAIR, K. B. RAMESH, M. SIVAKUMAR and J. THANISLASS (2015): Epidemiological and clinical studies on canine mammary tumors. *Indian. J. Vet. Res.* 24, 11-14.
60. HERMIDA, L. I., T. E. SÁNCHEZ, N. C. SÁNCHEZ, B. R. CORDERO, E. I. MORA and S. J. PINAR (2016): Marcadores Tumorales. *Rev. Clín. Med. Fam.* 9, 31-42.
61. HONRADO, E., A. OSORIO, J. PALACIOS and J. BENITEZ (2006): Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. *Oncogene* 25, 5837-5845.
62. HSU, W. L., H. M. HUANG, J. W. LIAO, M. L. WONG and S. C. CHANG (2009): Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. *Vet. J.* 180, 116-123.
63. JAILLARDON, L., J. ABADIE, T. GODARD, M. CAMPONE, D. LOUSSOUARN, B. SILIART and F. NGUYEN (2015): The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study. *BMC Cancer* 15, 664-677.
64. JENSEN, B. V., J. S. JOHANSEN and P. A. PRICE (2003): High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. *Clin. Cancer. Res.* 9, 4423-4434.
65. JÖCHLE, W. (1997): Prolactin in Canine and Feline Reproduction. *Reprod. Dom. Anim.* 32, 183-193.
66. KASZAK, I., A. RUSZCZAK, S. KANAFA, K. KACPRZAK, M. KRÓL and P. JURKA (2018): Current biomarkers of canine mammary tumors. *Acta. Vet. Scand.* 60, 66.
67. KHAN, A. and G. HASHMI (2015): Histology and functions of connective tissues: a review article. *University. J. Dent. Sci.* 1, 28-34.
68. KIL, D. Y. and K. S. SWANSON (2010): Endocrinology of obesity. *Vet. Clin. Small Anim.* 40, 205-219.
69. KIM, J. H., K. S. IM and N. H. KIM (2011): Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. *Vet. J.* 189, 318-322.
70. KONG, S. Y., J. H. KANG, Y. KWON, H. S. KANG, K. W. CHUNG, S. H. KANG, D. H. LEE, J. RO and E. S. LEE (2006): Serum HER-2 concentration in patients with primary breast cancer. *J. Clin. Pathol.* 59, 373-376.
71. KOSHIDA, K., T. UCHIBAYASHI, H. YAMAMOTO, K. YOKOYAMA and K. HIRANO (1996): A

- potential use of a monoclonal antibody to placental alkaline phosphatase (PLAP) to detect lymph node metastases of seminoma. *J. Urol.* 155, 337-341.
72. KRAWCZYK, N., M. BANYŚ, H. NEUBAUER, E. F. SOLOMAYER, C. GALL C, M. HAHN, S. BECKER, R. BACHMANN, D. WALLWIENER and T. FEHM (2009): HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. *Anticancer. Res.* 29, 4019-4024.
 73. KRISHNAMURTI, U. and J. F. SILVERMAN (2014): HER2 in Breast Cancer: A Review and Update. *Adv. Anat. Pathol.* 21, 100-107.
 74. KUMARAGURUPARAN, R., D. KARUNAGARAN, C. BALACHANDRAN, B. M. MANOHAR and S. NAGINI (2006): Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors. *Clin. Chim. Acta.* 365, 168-176.
 75. LAFLAMME, D. (1997): Development and validation of a body condition score system for dogs. *Canine Pract.* 22, 10-15.
 76. LANDIS, D. M., D. D. SEACHRIST, E. M. MONTAÑEZ-WISCOVICH, D. DANIELPOUR and A. R. KERI (2005): Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor- β signaling in ErbB2/ Neu-induced tumors from transgenic mice. *Oncogene* 24, 5173-5190.
 77. LEYLAND-JONES, B. (2002): Trastuzumab therapy for the metastatic patient: does the primary match? *Ann. Oncol.* 13, 993-994.
 78. LIM, H. Y., K. S. IM, N. H. KIM, H. W. KIM, J. I. SHIN and J. H. SUR (2015): Obesity, expression of adipocytokines, and macrophage infiltration in canine mammary tumors. *Vet. J.* 203, 326-331.
 79. LINDBLAD-TOH, K., C. M. WADE, T. S. MIKKELSEN et al. (2005): Genome sequence, comparative analysis and haplotype structure of the domestic dog. *Nature* 438, 803-819.
 80. LINDBLOM, A. and A. LILJEGREN (2000): Regular review: tumour markers in malignancies. *BMJ* 320 (7232), 424-427.
 81. LÜFTNER, D., C. LÜKE. and K. POSSINGER (2003): Serum HER-2/neu in the management of breast cancer patients. *Clin. Biochem.* 36, 233-240.
 82. MACEWEN, E. G., A. K. PATNAIK A, H. J. HARVEY and W. B. PANKO (1982): Estrogen Receptors in Canine Mammary Tumors Estrogen Receptors in Canine Mammary Tumors. *Cancer Res.* 42, 2255-2259.
 83. MACEWEN, E. G. (1990): Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. *Cancer. Metastasis. Rev.* 9, 125-136.
 84. MAFFEI, M., J. HALAAS, E. RAVUSSIN et al. (1995): Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. *Nat. Med.* 1, 1155-1161.
 85. MANGUIRE, H. C., C. JAWORSKY, J. A. COHEN, M. HELLMAN, D. B. WEINER and M. I. GREENE (1989): Distribution of neu (c-erbB-2) Protein in Human Skin. *The J. Invest. Dermatol.* 92, 786-790.
 86. MEIRELLES, R. G. (2010): Carcinoma em tumor misto da mama da cadela : Avaliação de aspectos morfológicos e perfil imunofenotípico. Dissertation. Patologia da Faculdade de Medicina, Universidade Federal de Minas Gerais.
 87. MERLO, D. F, L. ROSSI, C. PELLEGRINO et al. (2008): Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. *J. Vet. Intern. Med.* 22, 976-984.
 88. MICHEL, E, C. B. ROHRER, M. P. KOWALEWSKI, S. K. FELDMANN and I. M. REICHLER (2012a): Prolactin – to be reconsidered in canine mammary tumourigenesis? *Vet. Comp. Oncol.* 12, 93-105.
 89. MICHEL, E, S. K. FELDMANN, M. P. KOWALEWSKI, C. B. ROHRER, A. BOOS, F. GUSCETTI and I. M. REICHLER (2012b): Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas. *BMC Vet. Res.* 8, 2-8.
 90. MISDORP, W., R. W. ELSE, E. HELLMAN and E. LIPSCOMB (1999): Definitions and explanatory notes. In *Histological Classification of Mammary Tumors of the Dog and Cat.* Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, 18-27.
 91. MOASSER, M. M. (2007): The oncogene HER2; its signaling and transforming functions ant its role in human cancer pathogenesis. *Oncogene.* 426, 6469-6487.
 92. MOE, L. (2001): Population-based incidence of mammary tumours in some dog breeds. *J. Reprod. Fertil. Suppl.* 57, 439-443.
 93. MUHAMMADNEJAD, A., E. KEYHANI, P. MORTAZAVI, F. BEHJATI F and I. S. HAGHDOOST (2012): Overexpression of her-2/neu in malignant mammary tumors; translation of clinicopathological features from dog to human. *Asian. Pac J. Cancer. Prev.* 13, 6415-6421.
 94. MULLER, D. C. M., J. E. W. SCHOSSLER and M. PINHEIRO (2008): Adaptation of human body mass index for dogs. *Cienc. Rural.* 38, 1038-1043.
 95. MURUA-ESCOBAR, H., K. BECKER, J. BULLERDIEK and I. NOLTE (2001): The canine ERBB2 gene maps to a chromosome region frequently affected by aberrations in tumors of the dog (*Canis familiaris*). *Cytogenet. Cell. Genet.* 94, 194-195.
 96. OLIVIER, M., A. LANGERØD, P. CARRIERI et al. (2006): The Clinical Value of Somatic TP53 GeneMutations in 1,794 Patients with Breast Cancer. *Clin. Cancer. Res.* 12, 1157-1167.
 97. ONITILLO, A. A., J. M. ENGEL, R. T. GREENLEE and B. N. MUKESH (2009): Breast cancer subtypes based on ER/PR and Her2 expression: Comparison of clinicopathologic features and survival. *Clin. Med. Res.* 7, 4-13.
 98. OVERGAARD, J., M. YILMAZ, P. GULDBERG, H. L. LOTTE and J. ALSNER (2000): TP53 Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast Cancer. *Acta. Oncol.* 39, 327-333.
 99. PAGE, D. L., P. A. SCHUYLER, W. D. DUPONT, R. A. JENSEN, W. D. PLUMMER and J. F. JR, SIMPSON (2003): Atypical lobular hyperplasia

- as a unilateral predictor of breast cancer risk: a retrospective cohort study. *The Lancet* 361 (9352), 125-129.
100. PAGE, K. N. HAVA, B. WARD, J. BROWN, D. S. GUTTERY, C. RUANGPRATHEEP, K. BLIGHE, A. SHARMA, R. A. WALKER, R. C. COOMBES and J. A. SHAW (2011): Detection of HER2 amplification in circulating free DNA in patients with breast cancer. *Br. J. Cancer* 104, 1342-1348.
 101. PALLUD, C., J. M. GUINEBRETIERE, S. GUEPRATTE, K. HACENE, R. NEUMANN, W. CARNEY and M. F. PICHON (2005): Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. *Anticancer. Res.* 25 (2B), 1433-1440.
 102. PANG, L. Y. and D. J. ARGYLE (2009): Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. *Biochim. Biophys. Acta.* 1792, 380-391.
 103. PAOLONI, M. and C. KHANNA (2008): Translation of new cancer treatments from pet dogs to humans. *Nat. Rev. Cancer.* 8, 147-156.
 104. PAPEWALIS J., A. Y. NIKITIN and M. F. RAJEWISKY (1991): G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. *Nucleic. Acids. Research.* 19, 5452.
 105. PARK, S. H. Y. WANG, S. KIM, D. AHN, D. LEE, Y. CHO, K. H. PARK, D. JUNG, S. I. I. KIM and H. LEE (2014): Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues. *Int. J. Clin. Exp. Pathol.* 7, 6752-6759.
 106. PATSIKAS, M. N., M. KARAYANNOPOULOU, E. PALKIDYMI, L. G. PAPAZOGLU, P. L. PAPAPOULOU, S. I. TZEGAS, N. E. TZIRIS, D. G. KAITZIS, A. S. DIMITRIADIS and A. K. DESSIRIS (2006): The lymph drainage of the neoplastic mammary glands in the bitch: A lymphographic study. *Anat. Histol. Embryol.* 35, 228-234.
 107. PEREIRA, C. T., M. F. L. NAVARRO, J. WILLIAMS, B. W. DE MARTIN and P. P. BOMBONATO (2008): ^{99m}Tc-labeled dextran for mammary lymphoscintigraphy in dogs. *Vet. Radiol. Ultrasound.* 49, 487-491.
 108. PEREIRA, C. T., S. C. RAHAL, B. J. C. DE CARVALHO and A. A. C. M. RIBEIRO (2003): Lymphatic Drainage on Healthy and Neoplastic Mammary Glands in Female Dogs: Can it Really be Altered? *Anat. Histol. Embryol.* 32, 282-290.
 109. PEREZ-ALENZA, M. D., L. PEÑA, N. DEL CASTILLO and A. I. NIETO (2000): Factors influencing the incidence and prognosis of canine mammary tumours. *J. Small. Anim. Pract.* 41, 287-291.
 110. PÉREZ-LOSADA, J. (2011): Castellanos-Martín A, Mao JH. Cancer evolution and individual susceptibility. *Integr. Biol. (Camb.)* 3, 316-328.
 111. PERUZZI, D., G. MESITI, G. CILIBERTO G, N. LA MONICA and L. AURISICCHIO (2010): Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. *Vaccine* 28, 1201-1208.
 112. PET CENSUS (2016): Report. *Petplan*, 1-20.
 113. PINHO, S. S., S. CARVALHO, J. CABRAL, C. A. REIS and F. GÄRTNER (2012): Canine tumors: A spontaneous animal model of human carcinogenesis. *Transl. Res.* 159, 165-172.
 114. POPESCU, N. C., C. R. KING and M. H. KRAUS (1989): Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. *Genomics* 4, 362-366.
 115. PROSSNITZ, E. R., J. B. RTERBURN and L. A. SKLAR (2007): GPR30: a G protein-coupled receptor for estrogen. *Mol. Cell. Endocrinol.* 265-266, 138-142.
 116. PROSSNITZ, E. R. and M. MAGGIOLINI (2009): Mechanisms of estrogen signaling via GPR30. *Mol. Cell. Endocrinol.* 308, 32-38.
 117. QUEIROGA, F. L., M. D. PÉREZ-ALENZA, G. SILVAN, L. PEÑA, C. LOPES and J. C. ILLERA (2005): Role of steroid hormones and prolactin in canine mammary cancer. *J Steroid Biochem. Mol. Biol.* 94, 181-187.
 118. RAKHA, E. A., S. E. PINDER, J. M. BARTLETT et al. (2015): Updated UK Recommendations for HER2 assessment in breast cancer. *J. Clin. Pathol.* 68, 93-99.
 119. RAO, N. A. S. (2008): Characterization of Canine Mammary Carcinoma using Dog-Specific cDNA arrays. Dissertation. Faculty of Veterinary Medicine, Utrecht University.
 120. REDDY, G. K., V. K. JAIN, K. LEITZEL and J. A. O'SHAUGHNESSY (2004): Clinical Utility of Serum HER2/neu in Breast Cancer. *Clin. Breast Cancer* 5, 181-183.
 121. RENEHAN, A. G., J. FRYSTYK and A. FLYVBJERG (2006): Obesity and cancer risk: the role of the insulin-IGF axis. *Trends. Endocrinol. Metab.* 17, 328-336.
 122. RESSEL, L., R. PULEIO, G. R. LORIA, I. VANNOZZI, F. MILLANTA, S. CARACAPPA and A. POLI (2013): HER-2 expression in canine morphologically normal, hyperplastic and neoplastic mammary tissues and its correlation with the clinical outcome. *Res. Vet. Sci.* 94, 299-305.
 123. ROMERO, G. T., V. V. CASADO and A. J. CARRÚEZ (2002): Utilización de marcadores tumorales en Atención Primaria. *Medifam.* 12, 13-37.
 124. ROSS, J. S., J. A. FLETCHER, G. P. LINETTE, J. STEC, E. CLARK, M. AYERS, W. F. SYMMANS, L. PUSZTAL and K. J. BLOOM (2003): The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. *The Oncologist* 8, 307-325.
 125. ROWELL, J. L., D. O. MCCARTHY and C. E. ÁLVAREZ (2011): Dog models of naturally occurring cancer. *Trends. Mol. Med.* 17, 380-388.
 126. RUFO, J. G., A. GAZZANO and C. MARITI (2016): Prolactin In Female Domestic Dogs: A Mini-Review. *M. J. Vetr.* 1, 1-8.
 127. RUNGSIPIPAT, A., S. TATEYAMA, R. YAMAGUCHI, K. UCHIDA, N. MIYOSHI and T. HAYASHI (1999): Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. *J. Vet. Med. Sci.* 61, 27-32.
 128. RUTTEMAN, G. R., W. MISDORP, M. A. BLANKENSTEIN and W. E. VAN DEN BROM (1988): Oestrogen (ER) and progesteron receptors (PR) in mammary tissue of the female dog: different

- receptor profile in non-malignant and malignant states. *Br. J. Cancer*. 58, 594-599.
129. SAHABI, K., G. T. SELVARAJAH, M. M. NOORDIN, R. S. K. SHARMA and G. K. DHALIWAL (2015): Retrospective Histopathological Study of Canine Mammary Gland Tumours Diagnosed From 2006-2012 in University Putra Malaysia. *J. Vet. Malaysia* 27, 1-6.
 130. SALAS, Y., A. MÁRQUEZ, D. DIAZ and L. ROMERO (2015): Epidemiological Study of Mammary Tumors in Female Dogs Diagnosed during the Period 2002-2012: A Growing Animal Health Problem. *PLoS. One*. 10, e0127381.
 131. SANTILLÁN, B. J. G., Q. A. ORDÓÑEZ, Z. H. MENDIETA and O. L. M. GÓMEZ (2012): La leptina en la carcinogénesis mamaria. *Vías de señalización. Química Viva*. 11, 91-111.
 132. SAVINO, M., P. PARRELLA, M. COPETTI, R. BARBANO, R. MURGO, V. M. FAZIO, V. M. VALORI, M. CARELLA, M. GARRUBBA and S. A. SANTINI (2009): Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients. *Cell. Oncol.* 31, 203-211.
 133. SCHNEIDER, R., C. R. DORN and D. O. N. TAYLOR (1969): Factors Influencing Canine Mammary Cancer Development and Postsurgical Survival. *J. Natl. Cancer. Inst.* 43, 1249-1261.
 134. SELVARAJAN, S., B. H. BAY, M. J. CHNG and P. H. TAN (2004): The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: Any difference? *Ann. Acad. Med. Singapore* 33, 473-476.
 135. SHARPE, S. (2017): Modern pet ownership. *GlobalPETS Purple guide*, 1-4.
 136. SHIH, C., L. C. PADHY, M. MURRAY and R. A. WEINBERG (1981): Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature* 290 (5803), 261-264.
 137. SHINODA, H., M. E. LEGARE, G. L. MASON, J. L. BERKBIGLER, M. F. AFZALI, A. F. FLINT and W. H. HANNEMAN (2014): Significance of ER α , HER2, and CAV1 expression and molecular subtype classification to canine mammary gland tumor. *J. Vet. Diagn. Invest.* 26, 390-403.
 138. SHOFER, F. S., E. G. SONNENSCHNEIN, M. H. GOLDSCHMIDT, L. L. LASTER and L. T. GLICKMAN (1989): Histopathologic and dietary prognostic factors for canine mammary carcinoma. *Breast. Cancer. Res. Treat.* 13, 49-60.
 139. SIEGEL, P. M., D. L. DANKORT, W. R. HARDY and W. J. MULLER (1994): Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. *Mol. Cell. Biol.* 14, 7068-7077.
 140. SILVA, I. L. D., A. P. M. DIAS, A. C. BERTAGNOLLI, G. D. CASSALI and E. FERREIRA (2014): Analysis of EGFR and HER-2 expressions in ductal carcinomas in situ in canine mammary glands. *Arq. Bras. Med. Vet. Zootec.* 66, 763-768.
 141. SINGER, J., M. WEICHSELBAUMER, T. STOCKNER et al. (2012): Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. *Mol. Immunol.* 50, 200-209.
 142. SJÖGREN, S., M. INGANÄS, A. LINDGREN, L. HOLMBERG and J. BERGH (1998): Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. *J. Clin. Oncol.* 16, 462-469.
 143. SLAMON, D. J., G. M. CLARK, S. G. WONG, W. J. LEVIN, A. ULLRICH and W. L. MCGUIRE (1987): Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene. *Sci.* 235 (4785), 177-182.
 144. SLEECKX, N., H. DE ROOSTER, E. VELDHUIS KROEZE, C. VAN GINNEKEN and L. VAN BRANTEGEM (2011): Canine Mammary Tumours, an Overview. *Reprod. Domest. Anim.* 46, 1112-1131.
 145. SOARES, M., R. RIBEIRO, S. NAJMUDIN, A. GAMEIRO, R. RODRIGUES, F. CARDOSO and F. FERREIRA (2016): Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. *Oncotarget* 7, 17314-17326.
 146. SOMA, D., J. KITAYAMA, H. YAMASHITA, H. MIYATO, M. ISHIKAWA and H. NAGAWA (2008): Leptin augments proliferation of breast cancer cells via transactivation of HER2. *J. Surg. Res.* 149, 9-14.
 147. SONNENSCHNEIN, E. G., L. T. GLICKMAN, M. H. GOLDSCHMIDT and L. J. MCKEE (1991): Body conformation, diet, and risk of breast cancer in pet dogs: A case-control study. *Am. J. Epidemiol.* 133, 694-703.
 148. SORENMO, K. U., R. RASOTTO, V. ZAPPULLI and M. H. GOLDSCHMIDT (2011): Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. *Vet. Pathol.* 48, 85-97.
 149. STARKEY, M. P., T. J. SCASE, C. S. MELLERSH and S. MURPHY (2005): Dogs really are man's best friend - Canine genomics has applications in veterinary and human medicine! *Brief. Funct. Genomic. Proteom.* 4, 112-128.
 150. STEFANO, R., B. AGOSTARA, M. CALABRÒ, I. CAMPISI, B. RAVAZZOLO, A. TRAINA, M. MIELE and L. CASTAGNETTA (2004): Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. *Ann. NY. Acad. Sci.* 1028, 463-472.
 151. STEPHENS, J. M. (2012): The Fat Controller Adipocyte Development. *PLoS. Biol.* 10, 436-440.
 152. STØVRING, M., L. MOE and E. GLATTRE (1997): A population-based case-control study of canine mammary tumours and clinical use of medroxyprogesterone acetate. *APMIS* 105, 590-596.
 153. SZABO, C. I., L. A. WAGNER, L. V. FRANCISCO, J. C. ROACH, R. ARGONZA, M. C. KING and E. A. OSTRANDER (1996): Human, canine and murine BRCA1 genes: sequence comparison among species. *Hum. Mol. Genet.* 5, 1289-1298.
 154. TAMBURINI, B. A., S. TRAPP, T. L. PHANG, J. T. SCHAPPA, L. E. HUNTER and J. F. MODIANO (2009): Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. *PLoS. One* 4, e5549.
 155. TANG, J., S. LE, L. SUN, X. YAN, M. ZHANG, J. MACLEOD, B. LEROY, N. NORTHRUP, A. ELLIS, T. J. YEATMAN, Y. LIANG, M. E. ZWICK and S.

- ZHAO (2010): Copy number abnormalities in sporadic canine colorectal cancers. *Genome. Res.* 20, 341-350.
156. URIBE, C., S. OSMA and V. HERRERA (2012): Cancer incidence and mortality in the Bucaramanga metropolitan area 2003-2007. *Colomb. Méd.* 43, 290-297.
157. UVA, P., L. AURISICCHIO, J. WATTERS et al. (2009): Comparative expression pathway analysis of human and canine mammary tumors. *BMC Genom.* 10, 135.
158. VASCELLARI, M., K. CAPELLO, A. CARMINATO, C. ZANARDELLO, E. BAIONI and F. MUTINELLI (2016): Incidence of mammary tumors in the canine population living in the Veneto region (Northeastern Italy): Risk factors and similarities to human breast cancer. *Prev. Vet. Med.* 126, 183-189.
159. VERSTEGEN-ONCLIN, K. and J. VERSTEGEN (2008): Endocrinology of pregnancy in the dog: a review. *Theriogenology* 70, 291-299.
160. VIALE, G. (2012): The current state of breast cancer classification. *Ann. Oncol.* 23, 207-210.
161. WILSON, K. S., H. ROBERTS, R. LEEK, A. L. HARRIS and J. GERADTS (2002): Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. *Am. J. Pathol.* 161, 1171-1185.
162. WOLFF, A. C., M. E. HAMMOND, D. G. HICKS et al. (2013): Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J. Clin. Oncol.* 31, 3997-4013.
163. YANG, F., P. C. O'BRIEN, B. S. MILNE, A. S. GRAPHODATSKY, N. SOLANKY, V. TRIFONOV, W. RENS, D. SARGAN and M. A. FERGUSON-SMITH (1999): A complete comparative chromosome map for the dog, red fox, and human and its integration with canine genetic maps. *Genomics* 62, 189-202.
164. YARDEN, Y. and M. X. SLIWKOWSKI (2001): Untangling the ErbB signalling network. *Nat. Rev. Mol. Cell. Biol.* 2, 127-137.
165. YARDEN, Y. (2001). Biology of HER2 and its importance in breast cancer. *Oncology* 61 Suppl. 2, 1-13.

Tumor mliječne žlijezde kuja: kliničke implikacije sa specifičnim fokusom na HER-2 genu

Alejandro CLAVIJO-MALDONADO, Esp., Grupo de Investigación GEBIOME, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas y Naturales, Universidad de Caldas, Manizales, Colombia, Grupo de Propiedades Ópticas de Materiales, Departamento de Física y Química, Universidad Nacional de Colombia Sede Manizales, Manizales, Colombia; Enio FERREIRA, PhD, Instituto de Ciências Biológicas, Departamento de Patologia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brasil; Carlos VARGAS-HERNÁNDEZ, PhD, Grupo de Propiedades Ópticas de Materiales, Departamento de Física y Química, Universidad Nacional de Colombia Sede Manizales, Manizales, Colombia; Fredy A. RIVERA-PÁEZ, PhD, Grupo de Investigación GEBIOME, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas y Naturales, Universidad de Caldas, Manizales, Colombia

Tumor mliječne žlijezde kuja je jedna od najčešćih neoplazija u ženki u usporedbi s drugim vrstama. Ustvrđeno je nekoliko čimbenika rizika uključujući pasminu, genetsku predispoziciju, dob, reproduktivnu anamnezu, hormonalni utjecaj, hranidbu i tjelesnu kondiciju uz prethodne lezije mliječne žlijezde kao što su primjerice atipična hiperplazija mliječne žlijezde. U cilju uspostavljanja specifične terapije koja bi omogućila prihvatljivo vrijeme preživljavanja pacijenata važno je razumijevanje genetskih markera za spomenutu bolest kao i klinički pristup. Prekomjerna ekspresija HER-2 gena u kanida i ljudi povezana je s nepovoljnom kliničkom

prognozom, uglavnom s kratkim vremenom preživljavanja, premda nije jasna njihova klinička povezanost. Incidencija HER-2 u kuja može biti u rasponu od 29,7 % do 38 %. Međutim, prekomjerna ekspresija HER-2 nije nužno povezana sa zloćudnim procesima u tkivu mliječne žlijezde, premda ima ulogu u staničnoj proliferaciji. Naposljetku, kanidi su i dalje najvažniji modeli za komparativnu onkologiju u odnosu na ljude zbog velike sličnosti u spontanom izgledu i razvoju tumora kao i u visokoj homologiji u slijedu aminokiselina.

Ključne riječi: *c-erbB2, dijagnostika, zloćudni tumor mliječne žlijezde, prognoza, čimbenici rizika*